Beta Drugs Ltd

Beta Drugs Ltd Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Beta Drugs Ltd

₹ 1,621 -0.85%
04 Oct - close price
Company website NSE - SME: BETA
About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Key Points

Market Position
The company is ranked among the top 10 oncology companies, and many of its key products are ranked among the top 5 in their respective categories. [1]

Website NSE - SM
  • Market Cap ₹ 1,559 Cr.
  • Current Price ₹ 1,621
  • High / Low ₹ 1,985 / 892
  • Stock P/E 42.8
  • Book Value ₹ 163
  • Dividend Yield 0.00 %
  • ROCE 32.8 %
  • ROE 26.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 35.3% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.0%

Cons

  • Stock is trading at 9.92 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024
47 44 51 65 88 96 112 115 141 154
37 36 41 51 68 73 86 88 108 127
Operating Profit 9 8 11 14 20 23 27 26 33 27
OPM % 20% 19% 21% 22% 23% 24% 24% 23% 23% 18%
0 0 0 0 0 0 0 0 1 1
Interest 1 2 1 1 1 1 1 1 1 1
Depreciation 2 2 3 4 3 4 5 6 5 4
Profit before tax 7 5 7 9 16 18 21 20 27 22
Tax % 27% 14% 21% 30% 28% 27% 25% 25% 25% 25%
5 4 5 7 12 13 16 15 20 17
EPS in Rs 5.33 4.46 5.39 6.80 12.22 13.61 16.47 15.48 20.67 17.23
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
51 66 91 116 184 227 296
41 54 73 91 141 174 236
Operating Profit 9 12 18 25 43 53 60
OPM % 19% 18% 20% 21% 23% 23% 20%
0 0 0 0 1 1 1
Interest 1 1 3 2 2 2 3
Depreciation 2 3 4 7 7 10 10
Profit before tax 7 8 12 16 34 41 49
Tax % 1% -2% 21% 27% 28% 25% 25%
7 8 9 12 25 31 36
EPS in Rs 7.82 9.30 9.80 12.19 25.83 31.95 37.90
Dividend Payout % 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 35%
3 Years: 37%
TTM: 30%
Compounded Profit Growth
10 Years: %
5 Years: 35%
3 Years: 46%
TTM: 19%
Stock Price CAGR
10 Years: %
5 Years: 91%
3 Years: 47%
1 Year: 61%
Return on Equity
10 Years: %
5 Years: 26%
3 Years: 28%
Last Year: 26%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 9 9 10 10 10 10 10
Reserves 24 32 48 59 83 113 148
8 20 23 17 21 20 15
9 22 28 31 45 55 82
Total Liabilities 50 83 107 118 158 198 254
13 18 44 40 55 63 65
CWIP 1 15 0 3 0 0 0
Investments 0 0 0 1 1 1 0
35 50 63 74 102 135 190
Total Assets 50 83 107 118 158 198 254

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
17 0 8 19 30 23 31
-11 -21 -15 -6 -22 -19 -14
5 12 9 -8 -1 -2 -7
Net Cash Flow 12 -9 2 5 7 2 9

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 104 139 128 106 90 101 98
Inventory Days 37 104 102 100 87 106 122
Days Payable 81 143 119 127 123 139 145
Cash Conversion Cycle 60 100 111 79 53 68 75
Working Capital Days 75 100 95 88 70 88 86
ROCE % 18% 21% 22% 36% 34% 33%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
66.68% 66.71% 66.71% 66.71% 66.71% 66.71% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73%
0.00% 0.00% 0.00% 0.00% 0.29% 0.29% 0.29% 0.29% 0.32% 0.32% 0.32% 0.90%
0.28% 0.29% 0.29% 0.29% 0.04% 0.04% 0.04% 0.04% 0.02% 0.02% 0.06% 0.12%
33.03% 33.01% 33.00% 33.00% 32.96% 32.96% 32.94% 32.93% 32.93% 32.92% 32.87% 32.25%
No. of Shareholders 5426757621,2961,4071,4441,4241,4511,7221,9282,1162,323

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls